Virginiamycin m1

Found 1 Sample Hits

m/z	Adducts	Species	Organ	Scanning	Sample
564.338	[M+K]+ PPM:12.8	Homo sapiens	esophagus	DESI ()	LNTO22_1_3 - MTBLS385 Resolution: 75μm, 121x68 Description

Virginiamycin M1 is an antibiotic belonging to the macrolide class, specifically classified under the streptogramin A group. It is produced by the bacterium Streptomyces virginiae. Virginiamycin M1 is also known as Pristinamycin IIA. Chemical and Structural Characteristics: Virginiamycin M1 has a complex chemical structure characterized by a macrocyclic lactone ring, which is a hallmark of macrolide antibiotics. Its molecular formula is C28H35N3O7, and it has a molecular weight of approximately 525.59 g/mol. Mechanism of Action: Like other macrolides, Virginiamycin M1 inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit of susceptible bacteria. This action prevents the translocation step in protein elongation, thereby inhibiting bacterial growth. Antibacterial Spectrum: Virginiamycin M1 is effective against a range of Gram-positive bacteria, including strains like Staphylococcus aureus and Streptococcus pneumoniae. It is particularly noted for its activity against certain multidrug-resistant bacteria, making it a valuable option in veterinary medicine and sometimes in human medicine for specific indications. Uses: Primarily, Virginiamycin M1 is used in veterinary medicine as a growth promoter and for the prevention and treatment of bacterial infections in livestock. In some cases, it is used in human medicine, although its use is more restricted due to the potential for developing resistance. Resistance and Pharmacokinetics: The use of Virginiamycin M1 can lead to the development of bacterial resistance, particularly if used improperly or excessively. Its pharmacokinetics involve good absorption and distribution in tissues, although specific details can vary depending on the species and route of administration. Safety and Side Effects: In veterinary use, Virginiamycin M1 is generally considered safe when used according to guidelines. Potential side effects in animals can include gastrointestinal disturbances, but these are relatively rare. Regulatory Status: The use of Virginiamycin M1 is regulated differently in various countries. In some regions, it is approved for use in animal feed to promote growth and prevent diseases, while in others, its use may be more restricted due to concerns about antibiotic resistance. Research and Development: Ongoing research is focused on understanding the mechanisms of action and resistance, as well as exploring potential new applications or formulations to improve its efficacy and safety.